Evidence map›Paper›PMID 39334205›Full record

ArticleBMC pulmonary medicine2024

Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.

L Jason Lobo, Yi Liu, Peide Li, Murali Ramaswamy, Aparna C Swaminathan, Srihari Veeraraghavan, Yanni Fan, Megan L Neely, Scott M Palmer, Amy L Olson and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01915511 recruitingnot on this map

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry

Typeobservational_patient_registrySponsorDuke UniversityRan2014 to 2031Enrolled3,000ConditionsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Progressive pulmonary fibrosis: the importance of identification and intervention.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

L Jason LoboUNC School of Medicine, Chapel Hill, NC, USA. jason_lobo@med.unc.edu.
Yi LiuBoehringer Ingelheim Pharmaceuticals, Inc, Ingelheim, Germany.
Peide LiBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Murali RamaswamyLeBauer Pulmonary and PulmonIx LLC at Cone Health, Greensboro, NC, USA.
Aparna C SwaminathanDuke Clinical Research Institute, Durham, NC, USA.
Srihari VeeraraghavanEmory Healthcare, Atlanta, GA, USA.
Yanni FanBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.
Scott M PalmerDuke Clinical Research Institute, Durham, NC, USA.
Amy L OlsonBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
ILD-PRO Registry investigators†

Funding

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) and run in collaboration with the Duke Clinical Research Institute (DCRI) and enrolling centres. N/A
6 · The paper itself

Abstract

backgroundTo assess the characteristics of patients enrolled in the ILD-PRO Registry.

methodsThe ILD-PRO Registry is a multicentre US registry of patients with progressive pulmonary fibrosis. This registry is enrolling patients with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis who have reticular abnormality and traction bronchiectasis on HRCT, and who meet criteria for ILD progression within the prior 24 months. Patient characteristics were analysed based on the number of patients with available data.

resultsOf the first 491 patients enrolled, the majority were white (75.4%) and female (60.6%); 47.4% had a history of smoking. Reported ILDs were autoimmune disease-associated ILDs (47.2%), hypersensitivity pneumonitis (17.5%), idiopathic non-specific interstitial pneumonia (9.1%), interstitial pneumonia with autoimmune features (8.9%), unclassifiable ILD (7.6%), other ILDs (9.7%). At enrolment, median (Q1, Q3) FVC % predicted was 62.2 (49.4, 72.4) and DLco % predicted was 39.2 (30.2, 49.2). Median (Q1, Q3) total score on the St. George's Respiratory Questionnaire was 50.8 (35.9, 64.7). The most common comorbidities were gastroesophageal reflux disease (61.1%) and sleep apnoea (29.6%). Overall, 64.5% of patients were receiving immunosuppressive or cytotoxic therapy, 61.1% proton-pump inhibitors, 53.2% oral steroids, 19.8% nintedanib and 3.6% pirfenidone.

conclusionsPatients enrolled into the ILD-PRO Registry have a variety of ILD diagnoses, marked impairment in lung function and health-related quality of life, and high medication use. Longitudinal data from this registry will further our knowledge of the course of progressive pulmonary fibrosis.

trial registrationClinicalTrials.gov, NCT01915511; registered August 5, 2013.

Indexed as

Disease ProgressionLung Diseases, InterstitialRegistriesAgedFemaleHumansIdiopathic Pulmonary FibrosisIndolesMaleMiddle AgedMulticenter Studies as TopicPulmonary FibrosisPyridonesQuality of LifeTomography, X-Ray ComputedUnited StatesIndolesnintedanibpirfenidonePyridonesClinical trialDisease progressionInterstitial lung diseasePulmonary fibrosis

Identifiers

PMID39334205
PMCPMC11438290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.